中国肿瘤生物治疗杂志2017，Vol.24Issue(9)：929-937,9.DOI:10.3872/j.issn.1007-385x.2017.09.001
靶向抗肿瘤单克隆抗体药物应用的现状和展望
The development trend of therapeutic monoclonal antibodies for cancer therapy
摘要
Abstract
Many advances in the treatment of cancer have been driven by the development of targeted therapies that inhibit oncogenic signaling pathways and tumor-associated angiogenesis,as well as by the therapies that activate immune system to unleash antitumor immunity.Many clinically approved therapies,including monoclonal antibodies,antibody-drug conjugates,bispecific antibodies and immune checkpoints,have become important strategies for cancer treatment.Recently,tumor immunotherapy is becoming more and more popular,and antibody medicines acquiring above mentioned immune-modulating effects,such as increasing tumor antigenicity or promoting intratumoral T cell infiltration,had achieved great clinical benefits;monoclonal antibody medicine in combination with tumor immunotherapy,molecular targeted antibody medicine,chemotherapy or small molecular inhibitors and even surgery,will further enlarge the application value of antibody medicines in tumor therapies.关键词
单克隆抗体/肿瘤免疫治疗/免疫检验点/药物联用/双特异性抗体Key words
monoclonal antibody/tumor immunotherapy/immune checkpoint/combination/bispecific antibody分类
医药卫生引用本文复制引用
张敏,李佳,俞德超..靶向抗肿瘤单克隆抗体药物应用的现状和展望[J].中国肿瘤生物治疗杂志,2017,24(9):929-937,9.基金项目
国家“重大新药创制”科技重大专项资助项目(No.2014ZX09201041-001).Project supported by the National Major Scientific and Technological Special Project for “Significant New Drugs Development”(No.2014ZX09201041-001) （No.2014ZX09201041-001）
